Navigation Links
Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer Patients
Date:1/8/2012

progression during Avastin® treatment, implying that combination therapy with VGX-100 and Avastin® could significantly improve treatment outcomes in cancer patients.

Circadian's wholly owned subsidiary, Vegenics Pty Ltd, owns worldwide rights to an extensive intellectual property portfolio covering the angiogenesis and lymphangiogenesis targets VEGF-C, VEGF- D and the receptor protein VEGFR-3.  Vegenics has also been granted exclusive worldwide rights to intellectual property filed by Schepens Eye Research Institute covering the use of anti-lymphangiogenic molecules for the treatment of Dry Eye Disease.Company Enquiries:

Media Enquiries – International:  

 Robert Klupacs

Lauren Glaser Managing Director - Circadian

The Trout Group LLC Tel: +61 (0) 3 9826 0399 or

251 Post Street, Suite 412 robert.klupacs@circadian.com.au 

San Francisco, CA 94108  

Tel +1 215 740 8468  

lglaser@troutgroup.comAbout Circadian Technologies LimitedCircadian (ASX:CIR; OTCQX:CKDXY) is a biologics drug developer focusing on cancer and 'front of the eye' disease therapies.  It controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth  Factor  (VEGF)-C and -D. The  applications for the  VEGF technology,  which functions in regulating blood and lymphatic vessel growth, are substantial  and broad. Circadian's internal product development programs are primarily focussed on  developing  VGX-100 (a human antibody against  VEGF-C) as a treatment for solid tumours, in particular glioblastoma and colorectal cancer, as well as for 'front of the eye' disease such as corneal neovascularisation and/or corneal allograft rejection.  Circadian has also licensed
'/>"/>

SOURCE Circadian Technologies Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Circadiance Launches Revolutionary New CPAP Tube
2. Circadian Receives FDA IND Approval to Begin Clinical Trials With VGX-100 for the Treatment of Cancer Patients With Solid Tumors
3. Circadian Files IND With FDA for VGX-100 for the Treatment of Cancer Patients With Solid Tumors
4. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
5. Ikaria® Commences Global Registration Trial for Bioabsorbable Cardiac Matrix
6. Coronado Biosciences Commences Public Trading on the OTC Bulletin Board
7. Hotspur Technologies Commences US Launch at Veith/AIM Conference in New York City
8. CryoLife Commences Tender Offer for All Outstanding Shares of Cardiogenesis Corporation
9. Unilife Commences Initial Production of Unifill Prefilled Syringe
10. Quest Diagnostics Commences Tender Offer for Acquisition of Celera
11. Milestone Scientific Inc. Commences Trading on the OTC Pink
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com ... available in its catalogue: The Market ... http://www.reportlinker.com/p02051938/The-Market-for-Medical-Devices-in-EMEA .html The European, Middle Eastern and ... medical devices. As part of its coverage, this ... concentrates on the EMEA medical device markets and ...
(Date:8/20/2014)... Aug 20, 2014 Reportlinker.com announces that ... its catalogue: Global Patient Scales Industry ... This report analyzes the worldwide markets for Patient ... Segments: Floor Scales, Infant & Baby Scales, Chair ... separate comprehensive analytics for the US, Canada, Japan, ...
(Date:8/20/2014)... 20, 2014 Glenmark Pharmaceuticals ... Pharmaceuticals Limited India (GPL), announces the discovery and ... clinical development candidate, GBR 1302, a HER2xCD3 bispecific ... the Glenmark Biologics Research Centre located in La ... is based on Glenmark,s innovative BEAT antibody technology ...
Breaking Medicine Technology:The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3
... Risk Frontline Elderly AML and in Combination with Cytarabine in Relapsed/Refractory ... for Tuesday, December 9 at 11:00 am ET to Discuss Phase ... , SAN FRANCISCO , Dec. 7 Sunesis ... of new data from two ongoing clinical trials demonstrating that the ...
... Dec. 6 Results from RESTORE 2, a,placebo-controlled, Phase ... the number of seizures in adult,patients with refractory partial-onset ... added to a patient,s current anti-epileptic drug (AED) therapy. ... experiencing,seizures despite taking stable doses of up to three ...
Cached Medicine Technology:Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 2Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 3Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 4Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 5Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 6Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 2Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 3Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 4Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 5
(Date:8/21/2014)... 2014 Teen substance abuse is long been ... The rising numbers of young adults falling victim to a ... a difference in the community, the new Troubled Teens Boca ... teens seeking to overcome something like teenage alcohol abuse ... teens find the best teen recovery facility to focus on ...
(Date:8/21/2014)... Drake University’s Phi Gamma Delta (FIJI) and Colleen’s ... research, according to Billy Cundiff, President of Colleen’s Dream ... the Cleveland Browns, says the money raised by the ... Foundation and will fund research to be conducted by ... of Gynecologic Oncology at the University of Iowa’s Holden ...
(Date:8/21/2014)... 21, 2014 Today, Fecbek.com, a leading ... new designs of wedding dresses. And all these elegant, ... designed by excellent designers. , A wedding dress or ... during a wedding ceremony. Color, style and ceremonial importance ... culture of the wedding participants. In order to satisfy ...
(Date:8/20/2014)... Skmen.com, the popular online supplier of men’s and ... party dresses online. Along with this, the company has ... all the fresh products are offered with great discounts and ... special offer before August 31. , Skmen.com has more ... A large proportion of its clothes are selling well in ...
(Date:8/20/2014)... NJ (PRWEB) August 21, 2014 ... Practitioners, today announced that Ethan Nadelmann, JD, PhD, ... Dr. Nadelmann is the founder and executive director ... in the United States promoting alternatives to the ... drug policy reform, both domestically and internationally, he ...
Breaking Medicine News(10 mins):Health News:New Helpline Provides Hope for Troubled Teens in Boca Raton 2Health News:Drake University’s Phi Gamma Delta (FIJI) and Colleen’s Dream Foundation Donate $10,000 to the University of Iowa’s Holden Cancer Center to Fight Ovarian Cancer 2Health News:Drake University’s Phi Gamma Delta (FIJI) and Colleen’s Dream Foundation Donate $10,000 to the University of Iowa’s Holden Cancer Center to Fight Ovarian Cancer 3Health News:Elegant Wedding Dresses Are for Sale at Fecbek.com 2Health News:Skmen.com: New Designs Of Mini Party Dresses Provided Online 2Health News:PAINWeek Welcomes Ethan Nadelmann, JD, PhD, as Keynote Speaker at 2014 Conference 2
... ANTONIO - Breast cancer is a multifaceted disease requiring ... adjuvant therapies. Data presented at the CTRC-AACR San Antonio ... Hormone Supplements Reduce Death from Breast Cancer , ... have been implicated in increased rates of breast cancer, ...
... are victorious in sham SEIU vote , Less ... while caregivers file over 125,000 protests , ... in a statewide vote of healthcare workers conducted by the ... workers overwhelmingly oppose their national union,s sham election. Ballots were ...
... shows , , FRIDAY, Dec. 12 (HealthDay News) -- ... their breast cancer returning after surgery may make ... difficult, a new study concludes. , Doctors typically ... on a standard risk-assessment tool, with four different ...
... just announced her resignation as President of the Texas Medical ... power by the TMB against good physicians. Kalafut,s tenure ... and stonewalling by the TMB and Governor Rick Perry. , ... said AAPS Executive Director Jane Orient. "AAPS has received ...
... for America,s Health (TFAH) commends the Institute of Medicine for their ... Century: Charting a New Course for a Healthier America ... federal government is responsible for protecting the health of Americans, but ... fixed," said Jeff Levi, PhD, Executive Director of TFAH. "The ...
... 12th annual holiday gala The,Teddy Bear Ball, The ... Steve,Mosko, President of Sony Pictures Television in recognition ... with special needs. Grammy(R),winning singer-songwriter Kenny Loggins electrified ... Heart. Long standing friend and colleague of,nearly 30 ...
Cached Medicine News:Health News:Patient management: Quality of life and beyond 2Health News:Free Choice? Not For SEIU Members in California 2Health News:Risk Info for Breast Cancer Patients Too Confusing 2Health News:AAPS Applauds the Resignation of TMB President Roberta Kalafut, Mari Robinson Should Resign Next 2Health News:Trust for America's Health Applauds New IOM Report on Improving the U.S. Department of Health and Human Services for the 21st Century 2Health News:The Help Group's Teddy Bear Ball Salutes Sony Pictures Television President, Steve Mosko and Features Performance by Kenny Loggins 2
... Freedom leg bags are part ... a versatile line of leg bags, ... the varied needs of our customers. ... several sizes, and constructed of 100% ...
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
... line of Personal Catheters® ... you would choose for ... configurations - standard, antibacterial, ... - are based on ...
The Antibacterial Personal Catheter® features a unique silicone composition that provides an antibacterial coated soft outer layer of silicone combined with a firm inner layer....
Medicine Products: